Dr TEJASWINI ADADA

• European Society for Medical Oncology (ESMO)
• American Society for Clinical Oncology (ASCO)
• Indian Society of Medical and Paediatric Oncology (ISMPO)
• Indian Society of Bone Marrow Transplantation (ISBMT)
• Oxford Executive Education Network (Oxford said business school)
• Oxford guild
• ISB Healthcare Leadership Network(Indian school of business)

1. Digital Health Initiative
   • Feasibility study for early cancer detection in rural India
   • Development of AI-driven personalized rehabilitation programs
2. Strategic Growth Project
   • Expanding oncology centers with AI integration
   • Developing public-private partnerships for cancer care access
3. Academic Research
   • Leading studies in advanced cancer treatments
   • Investigating CDK4/CDK6 Inhibitors in breast cancer
   • Developing AI applications in oncology

• Consultant medical oncologist, and hematologist at Mallareddy Cancer Hospital and Research Institute
• Co-founder and Director – “Cancer Conscious”
• Co-founder of MEDHIC.AI (AI innovators in oncology and healthcare)
• Senior Executive Management in SGKEPC: Operations, Strategy Development
• Oncology Educator, Cancer Researcher, Entrepreneur in the Healthcare Industry

Current position: Consultant medical oncologist and hematologist, Mallareddy Cancer Hospital and Research Institute.

Previous: Consultant Medical Oncologist and Hematologist

HCG Cancer Centre, Visakhapatnam

• Direct comprehensive cancer care programs
• Lead multidisciplinary tumor boards
• Implement innovative treatment protocols
• Develop center-wide clinical guidelines
• Supervise clinical research initiatives

Ramaiah Medical College, Bengaluru (2020–2023)

• Specialized in oncology programs including BMT services
• Directed academic programs for postgraduate education
• Established research protocols and clinical trials
• Managed quality improvement initiatives

• ESMO International Conference 2022
• ISMPO-ISOCON 2022
• Regular speaker at healthcare management forums
• Completed certification in genetic counseling for cancer patients (KNOWMICS)
• Participated in many biomedical research conferences

Research Publications

• Poster presentation in APICON 2018, Bangalore – “PYREXIA OF UNKNOWN ORIGIN: RARE PRESENTATION OF ADULT ONSET STILL DISEASE”
• Poster presentation in APICON 2018, Bangalore – “PYREXIA OF UNKNOWN ORIGIN IN A YOUNG GIRL: RHEUMATOID NODULES”
• Thesis: The study of risk factors, symptomatology, and radiological profile in posterior circulation stroke
• Oral Paper Presentation at ISMPO-ISOCON 2022, Chennai – “Dose Intensity and Tolerance of Modified FOLFIRINOX Regimen in Patients with Advanced Cancer”
• Delegate in lymphoma workshop – joint conference of ISMPO-ISOCON 2022, Hilton Hotel, Chennai
• Poster Presentation at ESMO International Conference, December 2022 – “Dose Intensity and Tolerance of Modified FOLFIRINOX Regimen in Patients with Advanced Cancer”
• Participated in the 4th Annual Meeting of the Indian Society for Blood & Marrow Transplantation (ISBMT 2023)
• Publication: Adadadara T, Majumdar S, Maka VV et al. – “Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer.” Annals of Oncology. 2022;33 442P(Suppl1):S1612
• Published in Annals of Oncology (2022): "Dose intensity and tolerance of modified FOLFIRINOX"
• Multiple ongoing research projects in clinical oncology and healthcare management

Medical Education

• DM Medical Oncology – Ramaiah Medical College, RGUHS (2020–2023)
• DNB General Medicine – Medicover Hospitals (2016–2019)
• Clinical Investigator Research Trainee – NUS, Singapore (2012–2013)
• MBBS – MNR Medical College & Gandhi Medical College (2005–2011)

Executive Education

• Senior Executive Leadership in Healthcare – Oxford University, Saïd Business School (Pursuing)
  • Healthcare system transformation
  • Strategic innovation management
  • Value-based care implementation
• Advanced Management Program in Healthcare – Indian School of Business (2025)
  • Healthcare operations management
  • Strategic planning and execution
  • Digital health implementation

• AI in cancer research (Cambridge University)
• PI and Co-I investigator led trials:
  • 1. An open-label, randomized, multi-center, three-period, three-treatment, three-sequence, single-dose, crossover, pharmacokinetic study of Mylan’s Irinotecan Liposomal Injection compared with Ipsen Biopharmaceuticals Inc.’s Onivyde and Les Laboratoires Servier's Onivyde in combination with 5-FU and leucovorin in patients with metastatic adenocarcinoma of the pancreas, previously treated with gemcitabine.
  • 2. A prospective, randomized, double-blind, multicentric, parallel group Phase-III clinical study to evaluate the efficacy, safety, and immunogenicity of BP01 (Bevacizumab) versus EU-approved Avastin® along with chemotherapy XELOX in metastatic colorectal cancer patients.
  • 3. A randomized, double-blind, multi-center, active-control, parallel group study to compare efficacy, safety, immunogenicity, and pharmacokinetics of Lupin’s Nivolumab (LUBT022) with Innovator’s Nivolumab in patients with locally advanced or metastatic non-small cell lung cancer.
  • 4. A single group, non-randomized, multicenter, interventional Phase-3 study to investigate efficacy, safety, and pharmacokinetics of Fibrogen-ITM (Human Fibrinogen Injection) for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in patients with congenital fibrinogen deficiency.
  • 5. A randomized, open-label, multi-center, two-treatment, two-period, two-sequence, fully replicate, cross-over, multiple dose, steady-state, bioequivalence study of Olaparib Tablets 150 mg (2×150 mg tablets) of Alembic Pharmaceuticals Limited, India with Lynparza® 150 mg Filmtabletten Olaparib (2×150 mg tablets) of AstraZeneca AB, Sweden, in adult patients with carcinoma of the ovary, breast, prostate, or adenocarcinoma of the pancreas under fed condition.
• Research with ICMR:
  • 1. "Comparative Analysis of Vaginal-Cervical Microbiome Dysbiosis Between Cervical Cancer Patients and Healthy Controls Using 16S rRNA Sequencing in Telangana, India."
  • 2. Serial hemogram-derived inflammatory biomarkers, Glasgow Prognostic Scores, and ECOG-PS scores during initial treatment of newly diagnosed breast and cervical cancer: A prospective Indian study.

Core Competencies

• Clinical Excellence in Oncology
• Healthcare Operations Management
• Digital Health Implementation
• Academic Program Development
• Research & Innovation Management
• Public-Private Partnerships
• AI Integration in Healthcare